Details

Autor(en) / Beteiligte

• Karadurmus, Nuri
• Paydas, Semra
• Esin, Ece
• Surmeli, Zeki Gokhan
• Yildiz, Birol
• Erturk, Ismail
• Nayir, Erdinc
• Dogan, Mutlu
• Sumbul, Ahmet Taner
• Barista, Ibrahim
• Gurkan, Emel
• Ocal, Ramazan
• Ferhanoglu, Burhan
• Ozgur, Gokhan
• Karakas, Yusuf
• Lacin, Sahin
• Ozaydin, Sukru
• Petekkaya, Halil Ibrahim
• Uskent, Necdet

Titel

Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

Ist Teil von

• Archives of medical science, 2021, Vol.17 (4), p.920-927

Ort / Verlag

Termedia Publishing House

Erscheinungsjahr

2021

Quelle

Elektronische Zeitschriftenbibliothek - Freely accessible e-journals

Beschreibungen/Notizen

• Introduction We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey.  Material and methods In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity. Results Ninety-nine patients with a median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B-cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a median of three lines of chemotherapy (range: 2–8) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% ( = 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%).  Conclusions Objective response rate of bendamustine was found to be 74.3% in relapsed/refractory HL and NHL patients. It appears to be an effective option as a salvage treatment for patients who have previously received multiple lines of therapy.